logo

Biolinerx Ltd. (BLRX)



Trade BLRX now with
  Date
  Headline
10/13/2021 8:32:39 AM BioLineRx Reports Positive Results From Study Positioning Motixafortide As Standard Of Care In Stem Cell Mobilization
8/18/2021 7:18:55 AM BioLineRx Reports Q2 Net Loss Of $6.8 Mln Same With Last Year
5/26/2021 7:15:53 AM BioLineRx Q1 Loss Per Share $0.02 Vs Loss $0.04 Last Year
5/4/2021 7:21:14 AM BioLineRx Announces Positive Top-Line Results From GENESIS Phase 3 Trial Of Motixafortide
4/15/2021 7:25:42 AM BioLineRx Says On Track To Report Final Data From Phase 3 GENESIS Trial Of Motixafortide
2/23/2021 7:18:00 AM BioLineRx FY Net Loss $30.02 Mln Vs. Net Loss $25.5 Mln Last Year
12/16/2020 6:03:36 AM BioLineRx Announces Results From Triple Combination Arm Of COMBAT/KEYNOTE-202 Clinical Study
11/23/2020 7:15:34 AM BioLineRx Q3 Net Loss $4.6 Mln Vs Loss $3.9 Mln Last Year
11/18/2020 7:17:38 AM BioLineRx Initiates Phase 1b Trial In Patients With ARDS Secondary To COVID-19 And Other Respiratory Viral Infections
10/30/2020 7:23:18 AM BioLineRx Announces Positive Results From Interim Analysis Of GENESIS Phase 3 Trial Of Motixafortide
10/29/2020 8:52:44 AM BioLineRx Begins Phase 2 Clinical Trial In First-Line Metastatic Pancreatic Cancer